CardioPharma Granted Global Patent to Combat Leading Cause of Death

CardioPharma Inc., a specialized pharmaceutical company focusing on cardiovascular drug development, announced a significant milestone with the issuance of US Patent 11,737,988 B2 by the United States Patent and Trademark Office (USPTO) on August 29, 2023. This patent, titled "Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture," adds to the company's expanding portfolio of intellectual property. Further patents on the same subject have been granted in various countries, including South Africa in 2022, and Australia, Armenia, Belarus, and the Russian Federation in 2024. Additionally, three more patents have been accepted in Canada, New Zealand, and Israel, and will be issued soon. CardioPharma is also actively seeking additional patents in key global markets to strengthen its international presence. All these patents have a 20-year term extending through April 17, 2039.

CardioPharma's product pipeline features some of the most widely used medications for preventing and treating cardiovascular disease. The flagship product, CardiaPill®, is a unique formulation that combines a cholesterol-lowering agent known as a statin, an Angiotensin-converting-enzyme (ACE) inhibitor, and an anti-platelet agent. Statins, which include well-known drugs such as Lipitor®, Zocor®, Pravachol®, and Crestor®, are used to manage cholesterol levels. ACE inhibitors, such as Altace®, Lotensin®, Capoten®, and Accupril®, are utilized to lower blood pressure. The company’s pipeline also includes combinations that employ Angiotensin II Receptor Blockers (ARBs) alongside different statins and other anti-platelet agents. These formulations are designed to offer simplicity in dosing, improved patient adherence, and significant cost savings for patients, healthcare providers, and payors globally, making them highly anticipated in the medical community.

CardioPharma Inc. aims to create combinatorial cardiovascular medications that are protected by patents, making it easier and more economical for doctors and patients to combat cardiovascular disease, the leading cause of death worldwide. The company's products are uniquely positioned in the global pharmaceutical industry for their cost-effectiveness, proven efficacy, and convenience. These medications not only promote patient adherence but also deliver superior clinical outcomes and economic advantages to all stakeholders involved.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!